Target family: Voltage-gated calcium channels  (Ca<sub>V</sub>) (type: vgic)
Target: Ca<sub>v</sub>1.1

Ligand: BAYK 8644 (Synthetic organic)
Interaction type: Activator
Action: None
Ligand approved: no
Median affinity:  -
Reference (Journal): Molecular properties of calcium channels.
Published in: Rev Physiol Biochem Pharmacol

Ligand: BAYK 8644 (Synthetic organic)
Interaction type: Activator
Action: None
Ligand approved: no
Median affinity:  -
Reference (Journal): Calcium currents, charge movement and dihydropyridine binding in fast- and slow-twitch muscles of rat and rabbit.
Published in: J Physiol (Lond.)

Ligand: Cd2+ (Inorganic)
Interaction type: Channel blocker
Action: Antagonist
Median affinity: 4.3 pIC50
Reference (Journal): Calcium currents in embryonic and neonatal mammalian skeletal muscle.
Published in: J Gen Physiol

Ligand: diltiazem (Synthetic organic)
Interaction type: Channel blocker
Action: Antagonist
Ligand approved: yes
Approval source: FDA (1982)
Primary target: yes
Median affinity: 4.199999809265137 pIC50
Reference (Journal): Effect of calcium antagonist drugs on calcium currents in mammalian skeletal muscle fibers.
Published in: J Pharmacol Exp Ther

Ligand: FPL64176 (Synthetic organic)
Interaction type: Activator
Action: None
Ligand approved: no
Primary target: no
Median affinity: 7.800000190734863 pEC50

Ligand: (+)-isradipine (Synthetic organic)
Interaction type: Gating inhibitor
Action: Antagonist
Ligand approved: no
Median affinity:  pIC50
Reference (Journal): Calcium currents in embryonic and neonatal mammalian skeletal muscle.
Published in: J Gen Physiol

Ligand: nifedipine (Synthetic organic)
Interaction type: Gating inhibitor
Action: Antagonist
Ligand approved: yes
Approval source: FDA (1981)
Primary target: no
Median affinity: 6.300000190734863 pIC50
Reference (Journal): Calcium currents, charge movement and dihydropyridine binding in fast- and slow-twitch muscles of rat and rabbit.
Published in: J Physiol (Lond.)

Ligand: nimodipine (Synthetic organic)
Interaction type: Gating inhibitor
Action: Antagonist
Ligand approved: yes
Approval source: FDA (1988)
Primary target: no
Median affinity: 6 pIC50

Ligand: nitrendipine (Synthetic organic)
Interaction type: Gating inhibitor
Action: Antagonist
Ligand approved: yes
Primary target: no
Median affinity: 6 pIC50
Reference (Journal): Calcium currents in embryonic and neonatal mammalian skeletal muscle.
Published in: J Gen Physiol

Ligand: (-)-(S)-BayK8644 (Synthetic organic)
Interaction type: Activator
Action: None
Ligand approved: no
Primary target: no
Median affinity: 7.760000228881836 pEC50

Ligand: [3H](-)devapamil (Synthetic organic)
Interaction type: Gating inhibitor
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity:  pKd
Reference (Journal): High-affinity binding of DTZ323, a novel derivative of diltiazem, to rabbit skeletal muscle L-type Ca++ channels.
Published in: J Pharmacol Exp Ther

Ligand: [3H](-)devapamil (Synthetic organic)
Interaction type: Gating inhibitor
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity:  pKd
Reference (Journal): (-)-[3H]Desmethoxyverapamil, a novel Ca2+ channel probe. Binding characteristics and target size analysis of its receptor in skeletal muscle.
Published in: FEBS Lett

Ligand: [3H](+)-cis-diltiazem (Synthetic organic)
Interaction type: Gating inhibitor
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity:  pKd
Reference (Journal): High-affinity binding of DTZ323, a novel derivative of diltiazem, to rabbit skeletal muscle L-type Ca++ channels.
Published in: J Pharmacol Exp Ther

Ligand: [3H](+)-cis-diltiazem (Synthetic organic)
Interaction type: Gating inhibitor
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity:  pKd
Reference (Journal): Ligand-induced accelerated dissociation of (+)-cis-diltiazem from L-type Ca2+ channels is simply explained by competition for individual attachment points.
Published in: J Biol Chem

Ligand: [3H](+)-isradipine (Synthetic organic)
Interaction type: Gating inhibitor
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 9.199999809265137 pKd
Reference (Journal): Increase of voltage-sensitive calcium channels and calcium accumulation in skeletal muscles of streptozocin-induced diabetic rats.
Published in: Metab Clin Exp

Ligand: [3H](+)-isradipine (Synthetic organic)
Interaction type: Gating inhibitor
Action: Antagonist
Ligand approved: no
Median affinity: 9.7 pKd
Reference (Journal): Biochemical characterization of plasma membrane isolated from human skeletal muscle.
Published in: FEBS Lett

Ligand: SZ(+)-(S)-202-791 (Synthetic organic)
Interaction type: Activator
Action: None
Ligand approved: no
Primary target: no
Median affinity:  -

Ligand: verapamil (Synthetic organic)
Interaction type: Channel blocker
Action: Antagonist
Ligand approved: yes
Approval source: FDA (1981)
Primary target: yes
Median affinity: 5 pIC50
Reference (Journal): Effect of calcium antagonist drugs on calcium currents in mammalian skeletal muscle fibers.
Published in: J Pharmacol Exp Ther